Zobrazeno 1 - 10
of 86
pro vyhledávání: '"Dick, Pluim"'
Autor:
Karen de Jong, David Damoiseaux, Dick Pluim, Hilde Rosing, Jos H. Beijnen, Hans van Thienen, Thomas P.C. Dorlo, Alwin D.R. Huitema, Frédéric Amant
Publikováno v:
Biomedicine & Pharmacotherapy, Vol 166, Iss , Pp 115354- (2023)
Nivolumab is an immunotherapeutic monoclonal antibody (mAb) that is used for the treatment of several types of cancer. The evidence on its use during lactation is lacking. Here, we report on a 39-year-old woman with metastasized melanoma who was trea
Externí odkaz:
https://doaj.org/article/a6d2187b2f694b489900d86979fdf8cf
Autor:
Jan H.M. Schellens, Jos H. Beijnen, Wim W. ten Bokkel Huinink, Hilde Rosing, Dick Pluim, Nadja E. van Egmond-Schoemaker, Wandena S. Siegel-Lakhai, David S. Boss
Supplementary Data from Phase I Pharmacokinetic and Pharmacodynamic Study of Carboplatin and Topotecan Administered Intravenously Every 28 Days to Patients with Malignant Solid Tumors
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f36c9d0ed1e5d4002c17fae1ff6e120
https://doi.org/10.1158/1078-0432.22440754.v1
https://doi.org/10.1158/1078-0432.22440754.v1
Autor:
Baukelien van Triest, Marcel Verheij, Neeltje Steeghs, Jan H.M. Schellens, Conchita Vens, Manon Verwijs-Janssen, Dick Pluim, Ferry Lalezari, Adrianus J. de Langen, Erik van Werkhoven, Heike M.U. Peulen, Judi van Diessen, Michel M. van den Heuvel, Rosemarie de Haan
This file contains details on all late grade {greater than or equal to} 2 esophageal adverse events (I) and esophageal metabolic activity six weeks post-treatment (II).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c9380d91c3359b78ac353b04d720d78
https://doi.org/10.1158/1078-0432.22478508.v1
https://doi.org/10.1158/1078-0432.22478508.v1
Autor:
Baukelien van Triest, Marcel Verheij, Neeltje Steeghs, Jan H.M. Schellens, Conchita Vens, Manon Verwijs-Janssen, Dick Pluim, Ferry Lalezari, Adrianus J. de Langen, Erik van Werkhoven, Heike M.U. Peulen, Judi van Diessen, Michel M. van den Heuvel, Rosemarie de Haan
This file contains details on loco-regional control, progression free survival and overall survival split by treatment arm.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::07c4a5a3ad2b64ca20a2747a0193278e
https://doi.org/10.1158/1078-0432.22478502
https://doi.org/10.1158/1078-0432.22478502
Autor:
Baukelien van Triest, Marcel Verheij, Neeltje Steeghs, Jan H.M. Schellens, Conchita Vens, Manon Verwijs-Janssen, Dick Pluim, Ferry Lalezari, Adrianus J. de Langen, Erik van Werkhoven, Heike M.U. Peulen, Judi van Diessen, Michel M. van den Heuvel, Rosemarie de Haan
This file contains Supplementary Methods: radiotherapy details (I), treatment schedules (II), definition of Dose Limiting Toxicity (III) and a schedule of assessments (IV).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::31ec4c60067bbc8b36566f0bd907df6f
https://doi.org/10.1158/1078-0432.22478520.v1
https://doi.org/10.1158/1078-0432.22478520.v1
Autor:
Baukelien van Triest, Marcel Verheij, Neeltje Steeghs, Jan H.M. Schellens, Conchita Vens, Manon Verwijs-Janssen, Dick Pluim, Ferry Lalezari, Adrianus J. de Langen, Erik van Werkhoven, Heike M.U. Peulen, Judi van Diessen, Michel M. van den Heuvel, Rosemarie de Haan
This file contains details on the pharmacokinetic profile (I) and parameters (II) of olaparib.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::927fc0b9e1707a49daab0002ebe0ce92
https://doi.org/10.1158/1078-0432.22478499.v1
https://doi.org/10.1158/1078-0432.22478499.v1
Autor:
Baukelien van Triest, Marcel Verheij, Neeltje Steeghs, Jan H.M. Schellens, Conchita Vens, Manon Verwijs-Janssen, Dick Pluim, Ferry Lalezari, Adrianus J. de Langen, Erik van Werkhoven, Heike M.U. Peulen, Judi van Diessen, Michel M. van den Heuvel, Rosemarie de Haan
Purpose:To identify an MTD of olaparib, a PARP inhibitor, in combination with loco-regional radiotherapy with/without cisplatin for the treatment of non–small cell lung cancer (NSCLC).Patients and Methods:Olaparib dose was escalated in two groups:
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::683bd49325c289af8912ff3707498c93
https://doi.org/10.1158/1078-0432.c.6529965
https://doi.org/10.1158/1078-0432.c.6529965
Autor:
Jan H.M. Schellens, Jos H. Beijnen, Wim W. ten Bokkel Huinink, Hilde Rosing, Dick Pluim, Nadja E. van Egmond-Schoemaker, Wandena S. Siegel-Lakhai, David S. Boss
Purpose: Preclinical studies have shown that the combination of topotecan and carboplatin is synergistic. To evaluate the schedule dependency of this interaction, the following phase I trial was designed to determine the safety and maximum tolerated
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::07a184c2b5dbd6c1e1bdae501ee90c1d
https://doi.org/10.1158/1078-0432.c.6518044
https://doi.org/10.1158/1078-0432.c.6518044
Autor:
Baukelien van Triest, Marcel Verheij, Neeltje Steeghs, Jan H.M. Schellens, Conchita Vens, Manon Verwijs-Janssen, Dick Pluim, Ferry Lalezari, Adrianus J. de Langen, Erik van Werkhoven, Heike M.U. Peulen, Judi van Diessen, Michel M. van den Heuvel, Rosemarie de Haan
This file contains details on pulmonary function changes in diffusion tests (I) and spirometry tests (II), and the incidence of severe pulmonary adverse events by treatment arm (III).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::118f3d25e0885af1c3aed500734c8726
https://doi.org/10.1158/1078-0432.22478505
https://doi.org/10.1158/1078-0432.22478505
Autor:
Baukelien van Triest, Marcel Verheij, Neeltje Steeghs, Jan H.M. Schellens, Conchita Vens, Manon Verwijs-Janssen, Dick Pluim, Ferry Lalezari, Adrianus J. de Langen, Erik van Werkhoven, Heike M.U. Peulen, Judi van Diessen, Michel M. van den Heuvel, Rosemarie de Haan
This file contains the radiation doses to organs at risk (I) and details on systemic treatment (II).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a1995e43195b48b68724672a7742f979
https://doi.org/10.1158/1078-0432.22478517.v1
https://doi.org/10.1158/1078-0432.22478517.v1